2
|
Gupta AK, Langley RG, Lynde C, Barber K, Gulliver W, Lauzon G, Aspeslet LJ, Foster RT, Huizinga RB, Yatscoff RW. ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study. J Cutan Med Surg 2008; 12:268-75. [DOI: 10.2310/7750.2008.07060] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Background: Psoriasis is a chronic skin condition that can negatively affect a patient's quality of life (QoL), often hindering social functioning. ISA247, a novel psoriatic agent, has shown clinical efficacy in moderate to severe psoriasis sufferers, but its effect on QoL is currently not reported. Objective: The objective of this study was to assess the effect of ISA247 on the QoL in patients with stable, plaque-type psoriasis. Methods: A phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study assessed the effects of ISA247 doses of 0.5 mg/kg/d ( n = 77) or 1.5 mg/kg/d ( n = 83) compared with placebo ( n = 41) for 12 weeks. QoL was assessed using the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index (PDI) scales. Results: ISA247 treatment (pooled groups) significantly improved QoL scores as assessed by both the DLQI and the PDI compared with those receiving placebo ( p < .05). Treatment with the higher dose of 1.5 mg/kg/d demonstrated a significantly greater response to many of the QoL scales compared with the 0.5 mg/kg/d group ( p < .05). Conclusions: ISA247 appears to improve the QoL while also providing effective treatment for chronic, moderate to severe, plaque-type psoriasis.
Collapse
Affiliation(s)
- Aditya K. Gupta
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| | - Richard G. Langley
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| | - Charles Lynde
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| | - Kirk Barber
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| | - Wayne Gulliver
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| | - Gilles Lauzon
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| | - Launa J. Aspeslet
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| | - Robert T. Foster
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| | - Robert B. Huizinga
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| | - Randall W. Yatscoff
- From the Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON; Mediprobe Research Inc., London, ON; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS; Lynderm Research Inc., Markham, ON; The Dermatology Centre, Calgary, AB; NewLab Clinical Research Inc., St. John's, NF; University Dermatology Center, University of Alberta, Edmonton, AB; Isotechnika Inc., Edmonton
| |
Collapse
|